Current experimental studies and epidemiological findings on its relevance to AD were controversial, with some studies suggesting that higher serum total IGF-I levels and higher total IGF-I/IGFBP-3 ratios were associated with less cognitive decline (51). This evidence concerns the gene IGF1 and Alzheimer disease.